or Try an Advanced Search...

    ETF Components for PBE - PowerShares Dynamic Biotech & Genome


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    UTHR C 0.54 5.74
    ILMN C 1.37 5.64
    ALNY D 0.35 4.78
    AMGN D 0.47 4.70
    BIIB F 0.72 4.21
    NBIX C 0.90 4.18
    XNCR B 0.80 3.88
    EXEL B 0.32 3.86
    TGTX B 9.41 3.78
    BMRN F -0.35 3.76
    MNKD B -1.24 3.70
    NTRA A 0.97 3.56
    REGN F 0.43 3.38
    INCY C -1.13 3.35
    VCYT B 0.54 3.28
    ACAD C -2.67 3.06
    CPRX C -1.13 3.00
    BPMC C 0.78 2.91
    TECH F 2.31 2.89
    VCEL A 1.21 2.79
    OPK B -0.32 2.78
    RGEN D -0.06 2.76
    PTGX D 4.06 2.75
    QGEN D -0.10 2.59
    BCRX D -0.07 2.56
    HALO F -1.57 2.42
    COLL F 2.02 2.27
    CDNA D -0.49 1.92
    NVAX F 0.68 1.83
    MYGN F 0.20 1.61

    Represented by ETF Holdings

    Keywords: Biotechnology Biopharmaceutical Medicine Cancer Chemical Compounds Life Sciences Monoclonal Antibodies Clinical Development Immunology Monoclonal Antibody Nasdaq 100 S&P 500 Antibodies Autoimmune Disease Biology Infectious Diseases Lab Testing Pain Prostate Cancer Acid
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Drug Manufacturers - Major

    Recent News for PowerShares Dynamic Biotech & Genome & its Holdings

    Date Stock Title
    Nov 21 TECH Temu Parent PDD Stock Tumbles After Q3 Profit Miss, Company Cites Intensified Competition and External Challenges
    Nov 21 TECH How To Earn $500 A Month From Intuit Stock Ahead Of Q1 Earnings
    Nov 21 TGTX TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
    Nov 21 TECH Tesla Registrations Drop By Over 20% In October In EU, Possibly Hindering Its 2024 Global EV Delivery Target
    Nov 21 TECH SpaceX CEO Elon Musk Reveals Technical Glitch That Led Company To Drop Key Objective Of Starship's 6th Test Flight
    Nov 21 TECH Ray Dalio Says Pro-Trump Tech Companies Stand To Gain As Focus Shifts To Deregulation: Here's How Investors Should Brace For Impact
    Nov 21 TECH SafeRent Settles $2.3M Discrimination Lawsuit Over Alleged AI Screening Bias Against Low-Income Renters
    Nov 21 TECH Google's 'Unlawful Behavior' Stifles Market Entry For Rivals: DOJ Says Alphabet Must Sell Chrome To End Search Monopoly
    Nov 21 TECH Tesla Now Allows Users To Report Snow Accumulation, Blocked Stalls And Other Supercharger Issues Ahead Of Winter
    Nov 21 TECH Why SpaceX Opted For Standard Starship Landing Over Elon Musk's Innovative 'Chopsticks' Technique
    Nov 21 TECH Ford's JV Battery Plant In Kentucky Faces Unionization As 'Supermajority' Of Workers Sign Union Authorization Cards, Says UAW
    Nov 21 TECH Nvidia's Blackwell Set To Outpace Hopper? Here's What CEO Jensen Huang Predicts For 2025
    Nov 21 TECH Elon Musk's Neuralink Gets Green Light To Launch Brain Chip Trial In Canada: 'Recruitment Is Now Open'
    Nov 21 TECH Nvidia CEO Jensen Huang Says The Present Time Is 'The Beginnings Of Two Fundamental Shifts In Computing' As Blackwell Powers Explosive AI Demand
    Nov 21 TECH Nvidia Stock Holding Up Better Than Gary Black's Expectations Amid Blackwell Chip Delays And Q4 Whisper Number Miss: Here's Why
    Nov 20 TECH Nvidia Beats Q3 Revenue, EPS Estimates, Supply Constraints Ding Stock: Huang Says 'Age Of AI Is In Full Steam' (UPDATED)
    Nov 20 TECH Snowflake Q3 Earnings: Revenue Beat, EPS Beat, Guidance Raise, AI Acquisition, Anthropic Partnership And More
    Nov 20 ILMN Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
    Nov 20 MYGN Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
    Nov 20 AMGN AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
    The PowerShares Dynamic Biotechnology & Genome Portfolio (Fund) is based on the Dynamic Biotech & Genome IntellidexSM Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances biotechnology and genetic engineering and reseach. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.
    Exchange Traded Fund ETF Exchange Traded Funds Biotechnology Invesco Powershares Genetic Engineering Inter 10 Index Genome
    Back to the Main PBE Page...